Recent research highlights that combining two immune checkpoint inhibitors with chemotherapy can significantly improve treatment outcomes for patients with high-risk breast cancer. Specifically, a phase II trial revealed that the addition of the PD-1 inhibitor cemiplimab and the LAG-3 inhibitor fianlimab to neoadjuvant chemotherapy more than doubled the estimated pathologic complete response (pCR) rates in patients with early-stage ERBB2-negative breast cancer compared to those receiving chemotherapy alone.
Study Overview
The study involved 76 patients diagnosed with stage II or III, high-risk ERBB2-negative breast cancer. Participants were treated with cemiplimab and fianlimab alongside paclitaxel, followed by doxorubicin and cyclophosphamide before their surgical procedures. The outcomes were then compared to a control group of 350 patients from the I-SPY2 trial who received standard chemotherapy.
Mechanism of Action
Cemiplimab functions by targeting PD-1, while fianlimab targets LAG-3. Both are immune checkpoints that can inhibit the immune system’s ability to recognize and attack cancer cells. By blocking these pathways simultaneously, the combined treatment aims to enhance the immune system’s response against tumors.
Key Findings
The primary focus of the research was to measure pCR, which is defined as the absence of residual invasive cancer in the breast and lymph nodes at the time of surgery. The results showed that the estimated pCR rate for patients receiving the dual therapy rose from 21% with standard chemotherapy to an impressive 44% with the combined treatment.
The trial also noted significant improvements in specific subtypes of breast cancer. In triple-negative breast cancer (TNBC), the pCR rate increased from 29% with standard treatment to 53% in the combination group. For hormone receptor (HR)-positive/ERBB2-negative disease, the pCR rate climbed from 14% to 36%.
Immune Signature as a Predictive Tool
An intriguing aspect of the research was the examination of ImPrint, a 53-gene expression signature linked to immune activity. This signature may serve as a predictive tool for identifying patients most likely to respond favorably to the dual immunotherapy. Among the TNBC patients treated with cemiplimab and fianlimab, an astounding 83% of those with ImPrint-positive tumors achieved pCR, in contrast to just 28% of those who were ImPrint-negative.
The results were even more promising in the HR-positive/ERBB2-negative cohort, where 10 out of 11 patients with ImPrint-positive tumors achieved pCR, translating to an estimated response rate of 91%. These findings suggest that ImPrint could effectively identify a subgroup of patients who are particularly sensitive to immunotherapy, especially in HR-positive breast cancer, where historically, immune checkpoint inhibitors have been less effective.
Adverse Events and Safety Profile
Despite the promising efficacy, the combination therapy was associated with an increased incidence of immune-related adverse events. Adrenal insufficiency occurred in 21% of patients undergoing the combined treatment, with 11% experiencing grade 3 or 4 events. Additional adverse effects included hypothyroidism and a 4% incidence of diabetes. Notably, 69% of adrenal insufficiency cases emerged after the immunotherapy had concluded, indicating a potential for delayed immune-related toxicities.
Future Directions and Considerations
Preliminary exploratory analyses indicated that event-free survival and distant recurrence-free survival were comparable between the experimental and control groups. This observation underscores the need for extended follow-up and larger clinical trials to determine whether the increased pCR rates will translate into improved long-term patient outcomes.
The findings from this research underscore the substantial potential of combining PD-1 and LAG-3 inhibitors in treating high-risk breast cancer. Moreover, the identification of immune signatures like ImPrint could help tailor treatment strategies, optimizing patient outcomes while minimizing unnecessary exposure to toxicities.
Key Takeaways
- Dual immunotherapy using cemiplimab and fianlimab significantly enhances pCR rates in high-risk ERBB2-negative breast cancer patients.
- The study revealed pCR rates of 44% in the treatment group compared to 21% with standard chemotherapy.
-
ImPrint, a gene expression signature, may effectively identify patients likely to benefit from this combined treatment.
-
Increased immune-related adverse events were noted, emphasizing the need for careful monitoring and management.
-
Further research is essential to ascertain the long-term benefits of this immunotherapy approach in breast cancer treatment.
In conclusion, this innovative approach to breast cancer therapy not only demonstrates a promising increase in treatment efficacy but also opens avenues for more personalized medicine based on immune signatures. The ongoing evolution of immunotherapy continues to reshape the landscape of cancer treatment.
Read more → www.emjreviews.com
